Payment overview · 2025
General Payments
$53.61
3 reported records · 2 companies
Healthcare provider profile · identity verified
Albert R Boroughs, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROEVILLE, AL · NPI 1740283548
Verified facts
What the public records show
CMS Open Payments records show Albert R Boroughs, MD received $53.61 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.83 | 66.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.78 | 33.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.76 | 2 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 783 | 241 |
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 199 |
| Omeprazole | Omeprazole | 594 | 178 |
| Mounjaro | Tirzepatide | 511 | 76 |
| Lisinopril | Lisinopril | 444 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 416 | 107 |
| Losartan Potassium | Losartan Potassium | 409 | 123 |
| Metformin Hcl | Metformin Hcl | 357 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 113 |
| Gabapentin | Gabapentin | 321 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 97 |
| Potassium Chloride | Potassium Chloride | 297 | 96 |
| Tramadol Hcl | Tramadol Hcl | 254 | 59 |
| Meloxicam | Meloxicam | 253 | 79 |
| Furosemide | Furosemide | 246 | 89 |
| Methylprednisolone | Methylprednisolone | 246 | 159 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 235 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 74 |
| Simvastatin | Simvastatin | 225 | 63 |
| Glipizide Er | Glipizide | 201 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 55 |
| Cefdinir | Cefdinir | 183 | 128 |
| Amoxicillin | Amoxicillin | 178 | 137 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 45 |
| Fluconazole | Fluconazole | 157 | 58 |
| Sertraline Hcl | Sertraline Hcl | 144 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 44 |
| Lorazepam | Lorazepam | 135 | 20 |
| Ozempic | Semaglutide | 132 | 22 |
| Eliquis | Apixaban | 126 | 33 |
| Prednisone | Prednisone | 125 | 73 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 124 | 68 |
| Clonidine Hcl | Clonidine Hcl | 122 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 36 |
| Clonazepam | Clonazepam | 121 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 39 |
| Atenolol | Atenolol | 115 | 32 |
| Azithromycin | Azithromycin | 114 | 83 |
| Carvedilol | Carvedilol | 114 | 34 |
| Metformin Hcl Er | Metformin Hcl | 104 | 35 |
| Allopurinol | Allopurinol | 103 | 35 |
| Donepezil Hcl | Donepezil Hcl | 101 | 30 |
| Meclizine Hcl | Meclizine Hcl | 98 | 46 |
| Lovastatin | Lovastatin | 96 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 90 | 70 |
| Ezetimibe | Ezetimibe | 88 | 36 |
| Trazodone Hcl | Trazodone Hcl | 87 | 27 |
| Famotidine | Famotidine | 86 | 29 |
| Verapamil Er | Verapamil Hcl | 84 | 24 |
| Jardiance | Empagliflozin | 78 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 21 |
| Temazepam | Temazepam | 71 | 14 |
| Ibuprofen | Ibuprofen | 67 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 49 |
| Valsartan | Valsartan | 64 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | suppressed |
| Levofloxacin | Levofloxacin | 58 | 38 |
| Estradiol | Estradiol | 57 | 18 |
| Nifedipine Er | Nifedipine | 56 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 15 |
| Enalapril Maleate | Enalapril Maleate | 53 | 16 |
| Naproxen | Naproxen | 50 | 27 |
| Pregabalin | Pregabalin | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Linzess | Linaclotide | 49 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Finasteride | Finasteride | 47 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 19 |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 13 |
| Spironolactone | Spironolactone | 41 | 13 |
| Glipizide | Glipizide | 40 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 27 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 14 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Warfarin Sodium | Warfarin Sodium | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Indomethacin | Indomethacin | 30 | 11 |
| Nystatin | Nystatin | 30 | 22 |
| Alprazolam | Alprazolam | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Metronidazole | Metronidazole | 29 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | 12 |
| Diazepam | Diazepam | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.61 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FARXIGA, JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error